|
| Thursday, May 25, 2023 |
|
|
Avance Clinical Joins Global Health Summit Campaign for Faster Access to Life-Changing and Life-Saving Therapies |
| Avance Clinical the leading award-winning Australian and North American CRO that offers the programs ClinicReady and GlobalReady for early phase biotech companies to speed up the path to regulatory approval, has been invited to join the Global Health Summit campaign which will be featured on Reuters. more info >> |
|
| Tuesday, April 18, 2023 |
|
|
Avance Clinical CEO Joins Global BioPharma Panel for Evolution Europe Summit 2023 |
| Avance Clinical the leading award-winning Australian and North American biotech CRO that offers a GlobalReady program to early phase biotech companies to speed up the path to regulatory approval, has been invited to join the Evolution Europe Summit 2023 (Montreux, Switzerland 20 April - 21 April 2023). more info >> |
|
| Wednesday, January 11, 2023 |
|
|
Avance Clinical Celebrates GlobalReady Success as 40 Biotechs Join Program |
| More than 40 biotech clients are now taking advantage of Avance Clinical's GlobalReady program which delivers streamlined clinical development from early phase in Australia expanding to sites in North America for later phases. All with the one CRO and dedicated teams across both regions. more info >> |
|
| Wednesday, September 28, 2022 |
|
|
Avance Clinical Wins International Health Award for Biotech CRO Services |
| Avance Clinical, the leading Australian-based biotech CRO with US operations has won the South Australian Premier's Export Awards - International Health category. The award recognises excellence in clinical services exports. more info >> |
|
| Tuesday, September 6, 2022 |
|
|
Avance Clinical Announces North American CRO Acquisition to Expand Later Phase Services for Biotechs |
| Avance Clinical, the Australian CRO for biotechs, has expanded into North America with the acquisition of CRO partner company C3 Research Associates to enable biotech clients a seamless journey from early phase to later phase studies. Avance Clinical has backing from private equity group Riverside Company for their global expansion program. more info >> |
|
| Monday, August 29, 2022 |
|
|
Avance Clinical Sponsors Biotech Company of the Year Awards at Informa Pharma Intelligence Awards 2022 |
| Avance Clinical, the leading Australian CRO for international biotechs, is sponsoring two awards - Biotech Company of the Year Private and Public - at the Informa Pharma Intelligence Awards 2022 and is also a finalist for the Best Contract Research Organization in APAC. more info >> |
|
| Tuesday, April 19, 2022 |
|
|
Avance Clinical Finalist for Informa Pharma Intelligence Awards 2022 - Best Contract Research Organization in APAC |
| Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has been selected as a finalist for the Best Contract Research Organization in APAC by Informa Pharma Intelligence. more info >> |
|
| Thursday, March 31, 2022 |
|
|
Avance Clinical Announces New Office Opening in Melbourne |
| Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Melbourne to support its growing clinical team in the greater Melbourne region. more info >> |
|
| Wednesday, March 2, 2022 |
|
|
Avance Clinical Announces New Office Opening in Sydney |
| Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has opened new offices in Sydney to support its growing clinical team in the greater Sydney region. more info >> |
|
| Tuesday, January 18, 2022 |
|
|
Avance Clinical Announces Major PE Investment for US Expansion at Biotech Showcase 2022 |
| Avance Clinical, the largest premium Australian Contract Research Organisation (CRO) for international biotechs, has secured a significant investment from global private equity firm, The Riverside Company (Riverside), to support further regional and global expansion. The investment values the company in excess of $200m. more info >> |
|
|
|
